Comparative Pharmacology
Head-to-head clinical analysis: BRIMONIDINE TARTRATE versus LUCEMYRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIMONIDINE TARTRATE versus LUCEMYRA.
BRIMONIDINE TARTRATE vs LUCEMYRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic receptor agonist; reduces aqueous humor production and increases uveoscleral outflow by activating presynaptic alpha-2 receptors, inhibiting norepinephrine release and decreasing cAMP in ciliary epithelium.
LUCEMYRA (lofexidine) is a central alpha-2 adrenergic agonist that reduces the release of norepinephrine in the brain, thereby alleviating opioid withdrawal symptoms.
1 drop of 0.1% or 0.15% solution in the affected eye(s) twice daily, approximately 12 hours apart.
18 mg orally 5-6 times daily (maximum 108 mg/day) for 7-14 days then tapered over 4-6 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in adults; in neonates and infants, half-life may be prolonged (up to 8–12 hours) due to immature renal function.
Terminal half-life approximately 5-6 hours; no clinically significant accumulation with twice-daily dosing.
Renal excretion of unchanged drug and metabolites accounts for approximately 74% of the dose; fecal excretion accounts for approximately 22%. The remainder is eliminated via biliary secretion.
Renal: 63% as unchanged drug; fecal: 27% (mostly unchanged); biliary: minimal (<5%).
Category A/B
Category C
Alpha-2 Adrenergic Agonist
Alpha-2 Adrenergic Agonist